McKesson Corporation (MCK) is listed on NYSE and operates in the Medical - Distribution industry (Healthcare sector).
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
| Rating | Analysts |
|---|---|
| Strong Buy | 1 |
| Buy | 24 |
| Hold | 6 |
| Sell | 0 |
| Strong Sell | 0 |
McKesson Corporation, founded in 1833 and headquartered in Irving, Texas, provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes a range of pharmaceutical drugs and healthcare products, and offers management and technological solutions to specialty practices and pharmacies. The International segment provides distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment supplies medical-surgical products and logistics services to healthcare providers. The RxTS segment supports biopharma and life sciences partners with medication management and logistics solutions.
Over the past three fiscal years, the company has demonstrated robust revenue growth, with a consistent increase at a 13.9% CAGR, rising from $276.7 billion in 2023 to $359.1 billion in 2025. However, despite this top-line expansion, profitability metrics have shown a downward trend. Gross margin decreased by 0.8pp, operating margin by 0.4pp, and net margin by 0.4pp, indicating that the company faced challenges in maintaining cost efficiencies as it scaled. Earnings per share (EPS) exhibited inconsistency, ending slightly higher at $25.72 in 2025 compared to $25.04 in 2023, reflecting the impact of fluctuating margins. On the cash flow front, both operating cash flow (OCF) and free cash flow (FCF) increased, with OCF reaching $6.1 billion and FCF $5.2 billion by 2025, although FCF margin slightly declined by 0.2pp. Notably, the company improved its net debt position, reducing it from $2.6 billion to $1.7 billion, which, coupled with a strong interest coverage ratio of 18.0x, suggests solid financial health. Additionally, the company executed a significant share buyback, reducing the share count by 9.9%, which has positively impacted per-share metrics, enhancing shareholder value. Despite these achievements, liquidity remains a concern with a current ratio below 1, indicating potential short-term financial constraints.
Recent developments for McKesson Corporation have been dominated by strategic and financial activities. On April 20, McKesson announced the sale of a minority stake in its medical-surgical unit to Apollo Funds for $1.25 billion, a move that underscores the company's strategic focus on optimizing its business portfolio. This transaction is expected to provide McKesson with additional capital to invest in core areas of its business. In terms of financial performance, McKesson is anticipated to potentially exceed earnings expectations in its upcoming report, as suggested by recent analyses from Zacks Investment Research. This optimism is likely fueled by McKesson's robust operational cash flow, which has been reported at $10 billion annually, contributing to a 144% total stock return over the past three years. Additionally, insider and institutional trading activity has been notable, with DSG Capital Advisors LLC and Argo Wealth Advisory LLC increasing their holdings in McKesson. These transactions, along with increased short interest by 29.9% in March, indicate heightened investor interest and scrutiny. Overall, McKesson's recent strategic sale and strong financial performance position the company favorably in the market, while ongoing trading activities reflect active investor engagement.
The healthcare distribution industry, where McKesson operates, is currently experiencing robust growth driven by increasing demand for specialty pharmaceuticals and biopharma services. Key macro trends include the acceleration of drug innovation, particularly in oncology and specialty therapies, and the implementation of regulatory changes like the Inflation Reduction Act affecting Medicare Part D. Management identifies oncology and biopharma services as significant growth areas, leveraging their scale and expertise to meet evolving market needs. The industry faces headwinds from regulatory shifts and competitive pressures, but McKesson's strategic focus on community-based care and technology-driven efficiencies positions it well to navigate these challenges. Consistently, across both calls, management emphasized the importance of regulatory engagement and innovation in maintaining competitive advantage.
McKesson's recent performance has been strong, with double-digit growth in revenue and adjusted EPS. This success is attributed to strategic initiatives in oncology and biopharma services, as well as operational efficiencies driven by technology investments. The integration of acquisitions like Florida Cancer Specialists and Prism Vision has bolstered the oncology segment, contributing to significant revenue and profit growth. Management expressed satisfaction with the operational execution and the resilience of their diversified portfolio. Concerns were minimal, though there was acknowledgment of variability in illness season product demand. Between the calls, the narrative remained consistent, highlighting sustained momentum across core businesses and the successful execution of strategic priorities.
McKesson's growth strategy focuses on expanding its oncology and multispecialty platforms, enhancing biopharma services, and leveraging technology to improve operational efficiencies. Investments are being made in automation, AI, and infrastructure to support these goals. Management claims competitive advantages in scale, distribution capabilities, and a strong network of community providers. However, they acknowledge risks such as regulatory changes and market dynamics, including competition from other healthcare distributors. Analysts questioned the sustainability of margin improvements and the impact of regulatory changes, which management addressed by emphasizing ongoing investments and strategic partnerships. While the strategy is promising, execution risks and regulatory uncertainties present potential challenges. Long-term investors may be encouraged by the growth prospects in oncology and biopharma services but should be cautious of regulatory impacts and market competition.
In the second call, management confirmed progress on several initiatives mentioned earlier, such as the integration of acquisitions and the expansion of their oncology network. They met their guidance for revenue and adjusted EPS, reflecting strong operational execution. There was a consistent emphasis on technology investments and operational efficiencies across both calls. However, there was less discussion in the later call about specific regulatory challenges, which had been a focus previously. Overall, management delivered on their commitments, with no significant gaps noted between the calls.
- Monitor revenue growth in the oncology and multispecialty segment, expected to increase by 29-33% for fiscal 2026.
- Check operating profit growth in the prescription technology solutions segment, anticipated to rise by 14-18%.
- Verify progress on the separation of the medical-surgical business, targeted for completion by the second half of 2027.
- Assess the impact of technology investments on operational efficiency, particularly in AI-driven initiatives.
- Evaluate the effects of regulatory changes, such as the Inflation Reduction Act, on McKesson's financial performance.